Near-total reduction in verapamil bioavailability by rifampin. Electrocardiographic correlates.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Chest

• Publication date

  1988-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1378/CHEST.94.5.954PMID 3180898
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The influence of antituberculosis drugs on the plasma level of verapamil

  2004cited by this paper
• Drug interactions with the calcium-entry blockers.

  1987cited by this paper
• Drug interactions with the calcium-entry blockers.

  1987cited by this paper
• Calcium antagonists for chronic stable angina pectoris.

  1987cited by this paper
• Role of calcium antagonists in systemic hypertension.

  1987cited by this paper
• Calcium Modulators: Future Agents, Future Uses

  1987cited by this paper
• Calcium antagonists for Prinzmetal's variant angina, unstable angina and silent myocardial ischemia: therapeutic tool and probe for identification of pathophysiologic mechanisms.

  1987cited by this paper
• Update on rifampin drug interactions.

  1987cited by this paper
• The pharmacodynamic and pharmacokinetic differences of the D- and L-isomers of verapamil: implications in the treatment of paroxysmal supraventricular tachycardia.

  1986cited by this paper
• Verapamil infusions in the treatment of atrial tachyarrhythmias

  1986cited by this paper
• Clinical Pharmacokinetics of Verapamil, Nifedipine and Diltiazem

  1986cited by this paper
• Reduction of bioavailability of verapamil by rifampin.

  1985cited by this paper
• Verapamil-Rifampin Interaction

  1985cited by this paper
• First-Pass Elimination Basic Concepts and Clinical Consequences

  1984cited by this paper
• Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double-blind comparison of digoxin, propranolol and verapamil.

  1984cited by this paper
• Rifampin drug interactions.

  1984cited by this paper
• Induction of propranolol metabolism by rifampicin.

  1983cited by this paper
• Effects ofIntravenous andChronic Oral Verapamil Administration inPatients withSupraventricular Tachyarrhythmias

  1980cited by this paper
• Effects of Intravenous and Chronic Oral Verapamil Administration in Patients with Supraventricular Tachyarrhythmias

  1980cited by this paper
• Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man.

  1980cited by this paper
• High-performance liquid chromatographic analysis of verapamil. II. Simultaneous quantitation of verapamil and its active metabolite, norverapamil.

  1980cited by this paper
• Principles and practice of infectious diseases. Vols 1 and 2.

  1979cited by this paper
• Influence of rifampicin on drug metabolism: Differences between hexobarbital and antipyrine

  1977cited by this paper
• Commentary: a physiological approach to hepatic drug clearance.

  1975cited by this paper
• A physiological approach to hepatic drug clearance

  1975cited by this paper
• Statistical estimations in pharmacokinetics

  1974cited by this paper
• Paroxysmal supraventricular tachycardia.

  1973cited by this paper

• Quantitative Analysis of the Effect of Gastrointestinal Water Dynamics on Oral Drug Absorption using a Physiologically Based Integrated Liquid and Intestinal Absorption Drug (ILIAD) Pharmacokinetic Model.

  2026cites this paper
• A Dose‐Finding Study to Guide Use of Verapamil as an Adjunctive Therapy in Tuberculosis

  2023influential citation
• A dose-finding study to guide use of verapamil as an adjunctive therapy in tuberculosis

  2023cites this paper
• A Combination of Machine Learning and PBPK Modeling Approach for Pharmacokinetics Prediction of Small Molecules in Humans

  2023cites this paper
• Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P‐glycoprotein–cytochrome P450 3A4 dual substrates

  2021cites this paper
• Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System

  2020cites this paper
• A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug–Drug Interaction Studies

  2020cites this paper
• Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.

  2019cites this paper
• Effect of rifampin on enantioselective disposition and anti‐hypertensive effect of benidipine

  2019cites this paper
• Inhaled anti-tubercular therapy: Dry powder formulations, device and toxicity challenges

  2016cites this paper
• In Vitro Evaluation of Inhalable Verapamil-Rifapentine Particles for Tuberculosis Therapy.

  2016cites this paper
• Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs.

  2014cites this paper
• A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.

  2013cites this paper
• Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor.

  2013cites this paper
• Efflux-Mediated Multidrug Tolerance in Replicating Mycobacteria

  2012cites this paper
• Morbidity and Mortality Weekly Report

  2012cites this paper
• Predictive Utility of In Vitro Rifampin Induction Data Generated in Fresh and Cryopreserved Human Hepatocytes, Fa2N-4, and HepaRG Cells

  2011cites this paper
• Evaluation of Recombinant Cytochrome P450 Enzymes as an in Vitro System for Metabolic Clearance Predictions

  2009cites this paper
• Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction

  2008cites this paper
• Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients

  2007cites this paper
• An evaluation of the sensitivity of the Ames assay to discern low-level mutagenic impurities.

  2007cites this paper
• Drug interactions between antibiotics and select maintenance medications: seeing more clearly through the narrow therapeutic window of opportunity.

  2004cites this paper
• Pharmacokinetic Interactions with Rifampicin

  2003cites this paper
• American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

  2003cites this paper
• Clinically Significant Interactions with Drugs Used in the Treatment of Tuberculosis

  2002cites this paper
• Implications of cytochrome P450 interactions when prescribing medication for hypertension.

  2002cites this paper
• Clinically Significant Interactions with Drugs Used in the Treatment of Tuberculosis

  2002cites this paper
• Pharmacokinetic Aspects of Treating Infections in the Intensive Care Unit

  2001cites this paper
• Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction.

  1998cites this paper
• SXR, a novel steroid and xenobiotic-sensing nuclear receptor.

  1998cites this paper
• Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin

  1996cites this paper
• Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

  1996cites this paper
• Drug interaction and pharmacological considerations during anti-infective therapy in cancer patients.

  1995cites this paper
• Toxic effects and drug interactions of antimycobacterial therapy.

  1995cites this paper
• Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans

  1995cites this paper
• Intravenous verapamil kinetics in rats: Marked arteriovenous concentration difference and comparison with humans

  1993cites this paper
• Identification of P450 enzymes involved in metabolism of verapamil in humans

  1993cites this paper
• Comparison of the Pharmacokinetics and Electrocardiographic Effects of Sublingual and Intravenous Verapamil

  1992cites this paper
• Impact of food on the pharmacokinetics and electrocardiographic effects of sustained release verapamil in normal subjects.

  1992cites this paper
• Update on rifampin drug interactions. II.

  1992cites this paper
• β-adrenoceptor antagonists and antianginal drugs

  1991cites this paper
• Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects.

  1991cites this paper
• Pharmakologie und antihypertensive Wirksamkeit der Kalziumantagonisten

  1991cites this paper
• Calcium channel antagonists: part VI: Clinical pharmacokinetics of first and second-generation agents

  1989cites this paper
• Rifampin Use in Peritoneal Dialysis

  1989cites this paper
• Clinical Pharmacokinetics of First and Second-Generation Agents

  1989cites this paper
• Update on rifampin drug interactions.

  1987cites this paper